High­land who? Biotech gets a $200M war chest to crack the US AD­HD mar­ket

At sev­er­al points last year, Toron­to-based High­land Ther­a­peu­tics spot­light­ed da­ta from a pair of piv­otal Phase III stud­ies of Ben­jor­na (HLD-200) which they say pro­vid­ed clear ev­i­dence that a night­ly dose of the drug upped the per­for­mance of kids with AD­HD from morn­ing through night. Now, star­ing down a Ju­ly 30 PDU­FA date with the FDA, the low-pro­file biotech has raised $200 mil­lion to fund the com­mer­cial ramp-up, con­fi­dent that they’re now a few short steps from shak­ing up a ma­jor mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.